Mediwound (NASDAQ:MDWD) Releases Earnings Results, Misses Estimates By $0.01 EPS

Mediwound (NASDAQ:MDWD) issued its earnings results on Tuesday, May 21st. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01), Morningstar.com reports. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.60 million. Mediwound had a negative return on equity of 383.19% and a negative net margin of 18.43%.

Shares of Mediwound stock traded down $0.12 on Friday, reaching $3.75. 101,000 shares of the company’s stock were exchanged, compared to its average volume of 232,289. The stock has a market capitalization of $105.19 million, a price-to-earnings ratio of -7.65 and a beta of 0.80. Mediwound has a 52 week low of $3.61 and a 52 week high of $7.35. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.79 and a current ratio of 3.99.

Several institutional investors have recently made changes to their positions in the company. Oppenheimer & Co. Inc. increased its position in shares of Mediwound by 6.5% during the 1st quarter. Oppenheimer & Co. Inc. now owns 32,800 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 2,000 shares during the last quarter. Meitav Dash Investments Ltd. boosted its stake in Mediwound by 0.6% in the 1st quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock worth $2,993,000 after purchasing an additional 3,536 shares during the period. Sargent Investment Group LLC bought a new stake in shares of Mediwound during the 4th quarter valued at about $55,000. Morgan Stanley boosted its position in shares of Mediwound by 65.6% during the 1st quarter. Morgan Stanley now owns 36,584 shares of the biopharmaceutical company’s stock valued at $183,000 after acquiring an additional 14,489 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Mediwound by 73.5% during the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 16,840 shares during the last quarter. 30.78% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have issued reports on the company. Zacks Investment Research cut Mediwound from a “buy” rating to a “hold” rating in a report on Wednesday, March 27th. Oppenheimer set a $15.00 price target on Mediwound and gave the stock a “buy” rating in a report on Monday, March 25th.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Sundance Herald and is the property of of Sundance Herald. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://sundanceherald.com/2019/06/14/mediwound-mdwd-issues-earnings-results.html.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Further Reading: Recession

Earnings History for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply